Evidence map›Paper›PMID 38008684›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2024

A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI.

Eliana R Gill, Lauren E Bartlett, Tijana Milinic, Nora Burdis, Joseph M Pilewski, Jordan M Dunitz, Siddhartha G Kapnadak, Christopher H Goss, Kathleen J Ramos

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Eliana R GillDivision of Biobehavioral Nursing and Health Informatics, Dept of Nursing, University of Washington, Seattle WA, USA.
Lauren E BartlettDivision of Pulmonary, Critical Care, and Sleep Medicine, Dept of Medicine, University of Washington, Seattle WA, USA.
Tijana MilinicDivision of Pulmonary, Critical Care, and Sleep Medicine, Dept of Medicine, University of Washington, Seattle WA, USA.
Nora BurdisDivision of Pulmonary, Critical Care, and Sleep Medicine, Dept of Medicine, University of Washington, Seattle WA, USA.
Joseph M PilewskiDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Dept of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Jordan M DunitzDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Dept. of Medicine, University of Minnesota, Minneapolis, MN, USA.
Siddhartha G KapnadakDivision of Pulmonary, Critical Care, and Sleep Medicine, Dept of Medicine, University of Washington, Seattle WA, USA.
Christopher H GossDivision of Pulmonary, Critical Care, and Sleep Medicine, Dept of Medicine, University of Washington, Seattle WA, USA; Division of Pulmonary and Sleep Medicine, Dept of Pediatrics, University of Washington, Seattle WA, USA; Seattle Children's Research Institute, Seattle WA, USA.
Kathleen J RamosDivision of Pulmonary, Critical Care, and Sleep Medicine, Dept of Medicine, University of Washington, Seattle WA, USA.
University of Washington · USNeurobehavioral Systems · USUniversity of Minnesota · USUniversity of Pittsburgh · US

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI PRADEEP k SINGH · 2010 to 2026
$21.4M
Omics and Symptom Science Training ProgramT32NR016913 · NINR · UNIVERSITY OF WASHINGTON · PI CYNTHIA M DOUGHERTY, Margaret McLean Heitkemper · 2017 to 2026
$3.2M
Palliative Care Research Training GrantT32HL125195 · NHLBI · UNIVERSITY OF WASHINGTON · PI KROSS, ERIN KATHRYN, SHARMA, RASHMI K. · 2015 to 2024
$3.2M
Predicting survival and planning for lung transplantation in severe cystic fibrosisK23HL138154 · NHLBI · UNIVERSITY OF WASHINGTON · PI RAMOS, KATHLEEN JESSICA · 2017 to 2021
$947k
NHLBI NIH HHS K23 HL138154NHLBI NIH HHS T32 HL125195NIDDK NIH HHS P30 DK089507NINR NIH HHS T32 NR016913
6 · The paper itself

Abstract

People with CF (PwCF), particularly those with advanced lung disease (ALD), experience frequent respiratory symptoms. A major CF breakthrough was the approval of elexacaftor/tezacaftor/ivacaftor (ETI) in 2019, which has been shown to improve symptoms and lung function in the CF population, and decrease pulmonary exacerbations. The purpose of this study was to analyze longitudinal changes in respiratory symptoms over 24 months in ETI-treated and untreated PwCF with ALD Symptoms were measured among CF adults with ppFEV

Indexed as

Cystic FibrosisPyrrolidinesAdultAminophenolsBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorHumansLungMutationPyrazolesPyridinesAminophenolsBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorelexacaftorPyrazolesPyridinesPyrrolidinesCystic fibrosisCystic fibrosis transmembrane conductance regulator modulatorElexacaftor/tezacaftor/ivacaftorRespiratory symptoms

Identifiers

PMID38008684
PMCPMC10948304
OpenAlexW4388997482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.